Glycine receptor mouse mutants: model systems for human hyperekplexia. (15th October 2013)

• Record Type: Journal Article
• Authors: Schaefer, Natascha; Langlhofer, Georg; Kluck, Christoph J; Villmann, Carmen
• Is Part Of: British journal of pharmacology. Volume 170:Number 5(2013:Nov.)
• Page Start: 933
• Page End: 952
• Publication Date: 2013-10-15
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.12335
• Languages: English
• ISSNs: 0007-1188

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Human hyperekplexia is a neuromotor disorder caused by disturbances in inhibitory glycine‐mediated neurotransmission. Mutations in genes encoding for glycine receptor subunits or associated proteins, such as <italic>GLRA1</italic>, <italic>GLRB</italic>, <italic>GPHN</italic> and <italic>ARHGEF9</italic>, have been detected in patients suffering from hyperekplexia. Classical symptoms are exaggerated startle attacks upon unexpected acoustic or tactile stimuli, massive tremor, loss of postural control during startle and apnoea. Usually patients are treated with clonazepam, this helps to dampen the severe symptoms most probably by up‐regulating GABAergic responses. However, the mechanism is not completely understood. Similar neuromotor phenotypes have been observed in mouse models that carry glycine receptor mutations. These mouse models serve as excellent tools for analysing the underlying pathomechanisms. Yet, studies in mutant mice looking for postsynaptic compensation of glycinergic dysfunction via an up‐regulation in GABA<sub>A</sub> receptor numbers have failed, as expression levels were similar to those in wild‐type mice. However, presynaptic adaptation mechanisms with an unusual switch from mixed GABA/glycinergic to GABAergic presynaptic terminals have been observed. Whether this presynaptic adaptation explains the improvement in symptoms or other compensation mechanisms exist is still under investigation. With the help of spontaneous glycine receptor mouse mutants, knock‐in and knock‐out studies, it is possible to associate behavioural changes with pharmacological differences in glycinergic inhibition. This review focuses on the structural and functional characteristics of the various mouse models used to elucidate the underlying signal transduction pathways and adaptation processes and describes a novel route that uses gene‐therapeutic modulation of mutated receptors to overcome loss of function mutations.</p> </abstract>